Hosted on MSN12m
Lion TCR s Liocyx M004 Receives FDA Clearance to Launch Global Multicenter Phase 2 Clinical Trial in HBV Related Hepatocellular CarcinomaOn 12 Feb 2025, Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug Administration (FDA) to initiate an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback